JP2019505511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505511A5 JP2019505511A5 JP2018534782A JP2018534782A JP2019505511A5 JP 2019505511 A5 JP2019505511 A5 JP 2019505511A5 JP 2018534782 A JP2018534782 A JP 2018534782A JP 2018534782 A JP2018534782 A JP 2018534782A JP 2019505511 A5 JP2019505511 A5 JP 2019505511A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- agent
- expression
- activity
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 33
- 230000000694 effects Effects 0.000 claims 16
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 11
- 102100029216 SLAM family member 5 Human genes 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 6
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 230000036210 malignancy Effects 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 108091027757 Deoxyribozyme Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000003782 apoptosis assay Methods 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 230000005522 programmed cell death Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000004085 CLL/SLL Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- -1 antisense Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275378P | 2016-01-06 | 2016-01-06 | |
| US62/275,378 | 2016-01-06 | ||
| PCT/IL2017/050019 WO2017118985A1 (en) | 2016-01-06 | 2017-01-05 | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019505511A JP2019505511A (ja) | 2019-02-28 |
| JP2019505511A5 true JP2019505511A5 (https=) | 2020-02-13 |
Family
ID=58016750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534782A Pending JP2019505511A (ja) | 2016-01-06 | 2017-01-05 | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10828318B2 (https=) |
| EP (1) | EP3400068A1 (https=) |
| JP (1) | JP2019505511A (https=) |
| CN (1) | CN108697907A (https=) |
| AU (1) | AU2017204950A1 (https=) |
| CA (1) | CA3009127A1 (https=) |
| WO (1) | WO2017118985A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| RU2593715C2 (ru) | 2010-09-15 | 2016-08-10 | Рэндэлл Дж. МРСНИ | Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина |
| CN106470707A (zh) | 2014-05-07 | 2017-03-01 | 应用分子运输有限责任公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
| EP3711488A1 (en) | 2015-05-06 | 2020-09-23 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| US10828318B2 (en) | 2016-01-06 | 2020-11-10 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US10760075B2 (en) * | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| WO2020096695A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| CN111304316A (zh) * | 2020-03-04 | 2020-06-19 | 苏州大学 | 基因Bmal1在制备检测治疗炎症性肠病的产品中的应用 |
| JP2023516089A (ja) * | 2020-03-06 | 2023-04-17 | アレタ・バイオセラピューティクス・インコーポレイテッド | がんの治療のための組成物及び方法 |
| US20240180963A1 (en) * | 2021-04-05 | 2024-06-06 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
| CN115990252A (zh) * | 2021-10-18 | 2023-04-21 | 清华大学 | 通过阻断slam家族受体的信号来治疗肿瘤的组合物及其应用 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024008659A1 (en) * | 2022-07-04 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
| CN115807090B (zh) * | 2022-11-17 | 2025-06-17 | 中国医学科学院肿瘤医院 | Slamf9在肿瘤免疫治疗中的应用 |
| CN119857143A (zh) * | 2023-10-20 | 2025-04-22 | 天津济坤医药科技有限公司 | Cd84作为治疗靶点在制备防治炎症性肠病的药物中的应用 |
| CN119857137A (zh) * | 2023-10-20 | 2025-04-22 | 天津济坤医药科技有限公司 | 一种抗cd84抗体在制备预防和/或治疗炎症性肠病的药物中的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| CA2006008C (en) | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| CA2328457A1 (en) | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| GB0001309D0 (en) | 2000-01-20 | 2000-03-08 | Nestle Sa | Valve arrangement |
| WO2001055336A2 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Methods and materials relating to cd84-like polypeptides and polynucleotides |
| IL152416A0 (en) * | 2000-04-27 | 2003-05-29 | Smithkline Beecham Corp | Novel compounds |
| US20050025789A1 (en) | 2001-11-09 | 2005-02-03 | John Nieland | Allogenic vaccine that contains a costimulatory polypeptide-expresing tumor cell |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| EP2067402A1 (en) | 2007-12-07 | 2009-06-10 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Transponson-mediated mutagenesis in spermatogonial stem cells |
| WO2010035259A2 (en) | 2008-09-23 | 2010-04-01 | Yeda Research And Development Co. Ltd. | Compositions and methods for diagnosing and treating b-cll |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| CN109554350B (zh) | 2012-11-27 | 2022-09-23 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN106573976B (zh) * | 2014-02-06 | 2020-05-05 | 耶达研究及发展有限公司 | 抗cd84抗体、包含所述抗体的组合物及其用途 |
| US10828318B2 (en) | 2016-01-06 | 2020-11-10 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
-
2017
- 2017-01-05 US US16/068,172 patent/US10828318B2/en active Active
- 2017-01-05 WO PCT/IL2017/050019 patent/WO2017118985A1/en not_active Ceased
- 2017-01-05 JP JP2018534782A patent/JP2019505511A/ja active Pending
- 2017-01-05 AU AU2017204950A patent/AU2017204950A1/en not_active Abandoned
- 2017-01-05 EP EP17704549.9A patent/EP3400068A1/en active Pending
- 2017-01-05 CA CA3009127A patent/CA3009127A1/en active Pending
- 2017-01-05 CN CN201780015429.XA patent/CN108697907A/zh active Pending
-
2020
- 2020-11-05 US US17/089,769 patent/US11986488B2/en active Active
-
2024
- 2024-05-20 US US18/668,337 patent/US20240398847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505511A5 (https=) | ||
| Du et al. | CAR-T therapy in solid tumors | |
| Taki et al. | Tumor immune microenvironment during epithelial–mesenchymal transition | |
| Melamed et al. | Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies | |
| Perets et al. | Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer | |
| Ansell et al. | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | |
| Assouline et al. | Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial | |
| Wang et al. | Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model | |
| Tang et al. | Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors | |
| Swierczak et al. | The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor | |
| Vyas et al. | Antigen loss variants: catching hold of escaping foes | |
| US20190048084A1 (en) | Anti-pd-l1 combinations for treating tumors | |
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| WO2017118407A1 (en) | Anti-cd20 combinations for treating tumors | |
| JP2019533981A5 (https=) | ||
| Jiang et al. | The role of NcRNAs to regulate immune checkpoints in cancer | |
| EP3399982A1 (en) | Anti-egfr combinations for treating tumors | |
| JP2012515217A5 (https=) | ||
| Saluja et al. | Inflammation as a driver of hematological malignancies | |
| Kamrani et al. | Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells | |
| JP2019531268A5 (https=) | ||
| Duenas-Gonzalez et al. | Pharmacodynamics of current and emerging treatments for cervical cancer | |
| Xu et al. | Priming leukemia with 5-azacytidine enhances CAR T cell therapy | |
| JP2018532757A5 (https=) | ||
| Fayyaz et al. | Revolutionizing cancer treatment: the rise of personalized immunotherapies |